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C75, a recently derived compound that potently suppresses feeding and induces weight loss, has been proposed to act
mainly by inhibiting fatty acid synthase (FAS) in central neurons that control feeding. For example, normal, fasting-
associated, hypothalamic increases in neuropeptide Y (NPY)/Agouti-related protein (AGRP) expression and decreases in
proopiomelanocortin (POMC)/cocaine and amphetamine regulated transcript (CART) expression were reported to be blocked
by C75. Using loose-patch extracellular recording in acute slices, we tested the effect of C75 on anorexigenic POMC
neurons and orexigenic NPY neurons of the hypothalamic arcuate nucleus, which were identified by promoter-driven GFP
expression, as well as on feeding-unrelated cerebellar Purkinje neurons. We expected C75 to activate POMC neurons, inhibit
NPY neurons, and have no effect on Purkinje neurons. Instead, C75 activated all cell types, suggesting that it lacks target
specificity. This activation was probably not caused by FAS inhibition, because the classical FAS inhibitor, cerulenin, did not
have this effect when tested on POMC and NPY neurons. Nonspecific neuronal activation and resulting neurological effects
might contribute to the decreased feeding reported to follow centrally administered C75. Injection, ip, of C75 induced severe
loosening or liquefaction of stools, weight loss, and decreased food intake in both wild-type and melanocortin-4 receptor
knockout mice. In contrast, cerulenin failed to loosen stools, even at a molar dose over 9-fold greater than C75, and had a
much smaller effect on body weight. FAS inhibitory activity, by itself, seems to be insufficient to reproduce all of the effects of
ip-injected C75.
OBESITY IS A MAJOR and rapidly growing public health issue (1, 2, 3). However, nonsurgical treatments for obesity have
had little long-term success, largely because of homeostatic mechanisms that oppose decreases in adiposity (4, 5, 6). Early
results using C75, a novel fatty acid synthase (FAS) inhibitor, to induce weight loss were extremely promising. Originally
developed for its antitumor activity, C75 was designed to be a less reactive (and therefore potentially safer) form of the
classical FAS inhibitor, cerulenin (7). C75 powerfully suppressed feeding and induced rapid weight loss not only in lean mice
but also in mice that were obese because of leptin-deficiency (ob/ob) or consumption of a high-fat diet (8, 9). Moreover,
whereas regular administration of low doses of C75 produced rapid tachyphylaxis in lean animals, obese animals remained
sensitive, a characteristic of potentially great clinical utility (10). Because feeding was inhibited by both central and peripheral
administration of C75 (8, 10) and because C75 seemed to block fasting-induced changes in neuropeptide expression (11), a
central mechanism of action was proposed. These data were consistent with the critical role of the central melanocortin
system in regulation of both long-term energy homeostasis (12, 13) and satiety (14). These results also met with great
scientific interest, because they seemed to address a hypothesis that high intracellular malonyl-CoA concentration, as an
indicator of high cellular energy charge, modulates neuronal activity so as to inhibit further feeding (8, 15). Malonyl-CoA is a
key intermediate in fatty acid synthesis.
When fuel is abundant, cytosolic ATP, acetyl-CoA, and citrate are plentiful. In the committed step in fatty acid synthesis,
acetyl-CoA carboxylase adds a carboxyl group to acetyl-CoA to form malonyl-CoA in a reaction driven by ATP hydrolysis
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(Fig. 1). Subsequently, FAS serially adds two-carbon units to the growing fatty acid chain, a process usually beginning with
acetyl-CoA (C2) and ending with palmitate (C16). Feeding increases cytosolic malonyl-CoA concentration, both by increasing
its precursors and by increasing cytoplasmic citrate, which is an allosteric activator of acetyl-CoA carboxylase. Elevated
[malonyl-CoA] inhibits carnitine palmitoyltransferase I (CPT I, also carnitine acyltransferase I), the enzyme that translocates
long-chain fatty acids into mitochondria and makes their oxidation possible. In this way, malonyl-CoA also serves as a
signaling molecule that couples recent digestion of carbohydrate and/or protein to decreased fatty acid oxidation (16).
It has been hypothesized that elevated [malonyl-CoA] might act to signal the fed state in specialized cell types, causing
increased insulin secretion in pancreatic β-cells and modulating the activity of feeding-related neurons so as to inhibit further
feeding (8, 15, 17). According to this hypothesis, malonyl-CoA might act directly, or by inhibiting CPT I it might increase
cytoplasmic long-chain free fatty acids and diacylglycerol, both of which are potential signaling molecules or precursors.
Inhibiting FAS could increase [malonyl-CoA] both by substrate accumulation and by reducing cytosolic palmitoyl-CoA, a
molecule that normally opposes formation of malonyl-CoA by inhibiting translocation of citrate from mitochondria to cytosol,
and by blocking the activation of acetyl-CoA carboxylase by citrate (16) (Fig. 1). As predicted, C75 administered after a
bolus of glucose increased [malonyl-CoA] in liver 1 h later. It was then proposed that C75 suppresses feeding by increasing
[malonyl-CoA] in key feeding-related neurons, as predicted by the malonyl-CoA hypothesis (8).
Proopiomelanocortin (POMC)/cocaine and amphetamine regulated transcript (CART) neurons of the hypothalamic arcuate
nucleus inhibit feeding (13, 18). Fasting causes POMC and CART expression to fall in the arcuate nucleus (19, 20, 21, 22).
Also, certain manipulations that decrease feeding, such as leptin (21, 22, 23, 24) or LPS administration (25), increase
POMC/CART expression or cFOS expression in POMC/CART neurons. The POMC knockout mouse is obese (26), as are
POMC-deficient humans (27). The secreted POMC cleavage product that is most important in feeding is α-MSH, and the
relevant receptor knockouts, MC4-RKO (melanocortin 4 receptor) (13) and MC3-RKO (28, 29), are obese. It has been
estimated that over 4% of cases of severe pediatric obesity result from MC4-R haploinsufficiency (30, 31, 32).
Neuropeptide Y (NPY)/Agouti-related protein (AGRP) neurons, also located in the hypothalamic arcuate nucleus, are thought
to promote feeding. Fasting causes hypothalamic NPY and AGRP expression to increase greatly (33, 34), and both NPY
(35) and AGRP (36) cause profound increases in feeding when administered intracerebroventricularly. AGRP antagonizes
the anorexigenic effect of α-MSH at melanocortin receptors (37); and POMC and NPY/AGRP neurons send projections to
many of the same sites (38, 39). Furthermore, there is evidence of cross-talk between these two classes of arcuate neurons
(40); NPY/AGRP neurons are thought to provide GABAergic input to POMC neurons (12).
It has been reported that single peripheral doses of C75, although almost completely inhibiting feeding, were not followed by
the normal effects of fasting on neuropeptide expression. Instead of decreasing, POMC and CART expression increased
slightly, and the usual fasting-induced increases in NPY and AGRP expression were severely blunted (11). This seemed to
suggest that modulation of the activity of anorexigenic POMC/CART neurons and orexigenic NPY/AGRP neurons contributed
to the observed inhibition of feeding. However, contradictory results were obtained when C75 injections were continued for
several days (10) and when obese mice were used (11). We tested the in vitro electrophysiological effect of C75 on POMC
and NPY neurons, identified by their expression of fluorescent transgenes, in acute hypothalamic slice preparations. In
characterizing the actions of hormones and neuropeptides on arcuate neuronal activity, results reported using this
preparation have been highly consistent with in vivo results (12, 41, 42, 43). As a control, C75 was also tested on cerebellar
Purkinje neurons, which are unrelated to feeding. The importance of metabolic processes to the proposed mechanism of C75
made it necessary to record from neurons without intracellular disruption. Therefore, cellular activity was monitored by loose-
patch extracellular recording.
Animals
Arcuate nucleus POMC neurons were studied in mice hemizygous for a transgene in which the POMC promoter drives
expression of enhanced green fluorescent protein (EGFP) (12) (POMC-EGFP, 33–47 d old in single-cell experiments, 30–38
d old in preincubation experiments). These mice were also used to study Purkinje cells in cerebellar vermis and paravermis
(19–23 d old). Arcuate nucleus NPY neurons were studied in mice hemizygous or homozygous for a transgene in which the
NPY promoter drives expression of a fusion protein of tau and sapphire, a green fluorescent protein variant (44, 45) (NPY-
SAP, 31–37 d old). Within the arcuate nucleus, all sapphire fluorescent neurons seem to express AGRP mRNA (Dr. Lora
Heisler, Beth Israel Deaconess Medical Center and Harvard Medical School, personal communication). Both transgenes
were expressed in a C57BL/6J background. Both male and female mice were used to study each cell type, and procedures
were approved by the Oregon Health and Science University Animal Care and Use Committee.
Electrophysiology
Materials and Methods
Coronal slices of hypothalamus and sagittal slices of cerebellum were prepared 200-μm thick with a vibrating slicer (Leica
VT1000S) using standard techniques. Subsequently, slices were maintained in a submersion-type holding chamber at 34–35
C for the first 30 m, then at room temperature for at least another 30 min before use. After transferring slices to a recording
chamber (30 C), at least 10 m were allowed for equilibration before recording. Saline used for slice preparation and
maintenance contained (in mM): 126.18 NaCl, 3.1 KCl, 2 CaCl2, 1 MgCl2, 1 NaH2PO4, 26.2 NaHCO3, 10 glucose, and
16.24 sucrose; 320 mosmol/kg, pH 7.39 when gassed with 95% O2-5% CO2. In saline used for recording, sucrose was
omitted and replaced with (in mM): 1 kynurenic acid (ionotropic glutamate receptor antagonist), 1.05 NaOH, 0.1 picrotoxin
(GABAA receptor antagonist), and 14.09 (0.1%) total dimethylsulfoxide (DMSO). The recording chamber was approximately
0.7 ml in vol and was perfused at approximately 2.3 ml/m.
Loose-patch extracellular recordings (46) were performed by filling a patch pipette (Rpipette  1.4–1.8  MΩ) with recording
saline and loosely attaching it to an identified neuron (Rseal  2.1–8 MΩ) using epifluorescence and IR-DIC optics (Carl
Zeiss, Jena GmbH, Germany). The looseness of the seal helped to prevent spontaneous rupture of the patched membrane.
To counter the tendency for the patched membrane to be drawn further into the pipette and potentially destabilize over time,
a small amount of positive pressure from a short column of water was applied via tubing to the pipette holder. With this
technique, in contrast to whole-cell patch clamp and sharp microelectrode recording, cytosolic contents and processes are
undisturbed, and neuronal activity is affected by neither seal strength nor current injection through the pipette. This allows
unbiased measurements of basal spike frequency to be made. Because loose-patch recordings required a small amount of
membrane to be drawn into the tip of the patch pipette, recorded neurons could be unambiguously identified. Recordings
were conducted in current clamp mode at 100× gain and filtered at 5 kHz. Data were acquired at 10 kHz using an Axopatch
1D amplifier and Clampex 8.2 software (Axon Instruments, Union City, CA). Data were analyzed using Clampfit 8.2 (Axon
Instruments), Mini Analysis Program 5.3.8 (Synaptosoft, Decatur, GA), GraphPad Prism 2.0 (Graphpad Software, Inc., San
Diego, CA), and Excel 2000 (Microsoft Corp., Bellevue, WA). Spike frequency was calculated in 60-sec bins; 100 mM C75,
100 mM cerulenin, and 1000 mMcerulenin stock solutions in DMSO were stored in small aliquots at −78 C. C75 was a kind
gift of Dr. M. Daniel Lane, Johns Hopkins University, who indicated that the compound was more than 98% pure, based on
HPLC, mass spectrometry, and nuclear magnetic resonance data.
The basal spike frequency of individual POMC neurons ranged from 0 to over 3 Hz. A few neurons with basal frequencies
from 0.16–3.2 Hz were used to test the effect of C75 on single cells in long-term recordings. After at least 20 min of baseline
recording, the perfusion saline was switched to either C75 or a matched control. Baseline was calculated from the mean
frequency 0–20 min before drug/control application, and this was subtracted from each data point. Results for each cell were
quantified by measuring the mean change in spike frequency 34–44 min after drug/control application, and the slope of the
change in spike frequency (by linear regression) from 10–44 min after drug/control application.
In preincubation experiments, single hypothalamic or cerebellar slices were transferred from the room temperature holding
chamber to a 30-C preincubation chamber containing C75, cerulenin, or vehicle in 100 ml of continuously gassed recording
saline. After 60 min, the slice was transferred to a recording chamber and perfused with control (drug-free) recording saline.
After a 10-min equilibration, recordings of basal spike frequency were obtained from as many morphologically normal
neurons as possible for the next 50 min. Spike frequency was calculated from the first 120 sec of each recording. In the few
cases where aberrant spike patterns seemed to indicate failing cell health, recordings were rejected.
Feeding experiments
All in vivo experiments were conducted using singly housed mice. To determine the effect of C75 on normal mice, 2- to 3-
month-old, female, POMC-EGFP(Tg/+) and NPY-SAP(Tg/+) mice were distributed by age and genotype into control and test
groups, which differed in mean initial body weight by less than 1.7% (control, 19.9 ± 0.7 g; test, 19.6 ± 0.4 g). Because of
results from a pilot experiment, a paper towel was laid on the bedding of each cage to facilitate examination of feces. The
same frozen stock of C75 used for electrophysiological experiments was diluted in RPMI Medium 1640 (Invitrogen Corp.,
Carlsbad, CA) and ip injected into mice by a blinded investigator at a dose of 15 mg/kg in a total vol of 20 μl/g body weight.
Control mice were injected with RPMI containing an equal concentration of DMSO (2.95%). Injections were performed
approximately 1 h before lights out. Similar procedures were used for in vivo cerulenin experiments. The same DMSO
concentration and injection volume were used, and both injections and subsequent measurements were performed by a
blinded investigator. Cerulenin experiments used 1.5- to 2-month-old, male and female, C57BL/6J, POMC-EGFP/+ and
NPY-SAP/+ mice, distributed by age, gender, and genotype into four equivalent groups, which differed in initial body weight
by less than 1.3% (0, 30, 60, 120 mg/kg: 19.2 ± 1.2, 19.0 ± 1.2, 19.2 ± 0.8, 19.2 ± 1.0 g). C75 was also tested on 1-month-
old, male and female MC4-RKO mice (13) with procedures modified as follows. Because these mice are acutely sensitive to
stress (47), mice were conditioned with daily ip vehicle injections for 5 d before injection with 15 mg/kg C75. Injection vol
was 11.8 μl/g body weight, and DMSO concentration was 5%. In cerulenin and MC4-RKO experiments, bedding consisted
only of several layers of paper towels to facilitate examination of feces.
Statistical analysis
In all descriptions of results and in figures, data are presented as mean ± SEM. Results of statistical tests are described
in Results and in figure legends. The significance level of all tests was set at P = 0.05.
C75 induced a delayed activation of anorexigenic arcuate nucleus POMC neurons
Because C75 was hypothesized to act by causing an increase in cytosolic [malonyl-CoA], it was important to record from
neurons without perturbing their metabolic processes. Therefore, extracellular recordings of action potentials were made from
loose-patched POMC neurons of the hypothalamic arcuate nucleus. In all recordings, after a delay, C75 induced a steady
increase in spike frequency (Fig. 2). Especially at 100 μM C75, this increase seemed to be preceded by a small, transient
decrease in spike frequency. Consistent with the lipophilicity of C75, the increase in spike frequency was resistant to
washout (data not shown). C75-induced stimulation of POMC cells, whether measured as net increase in spike frequency or
as the slope of that increase, was statistically significant at both 50-μM and 100-μM doses (P< 0.001). The increases at 50
μM and 100 μM C75 were not significantly different from each other. Results (mean ± SEM) were as follows (change in spike
frequency, slope of change, number of cells): control, 0.22 ± 0.09 Hz, 0.0046 ± 0.0051 Hz/m, 8 cells; 50 μM C75, 2.05 ± 0.27
Hz, 0.077 ± 0.0079 Hz/m, 3 cells; 100 μM C75, 2.46 ± 0.62 Hz, 0.079 ± 0.018 Hz/m, 3 cells.
Preincubation in C75 increased the basal firing rate of arcuate nucleus POMC neurons
Taking advantage of the resistance of the effect of C75 to washout, we switched to a preincubation protocol to conserve our
limited supply of the compound (see Materials and Methods). Consistent with our earlier data, 60 min of preincubation with
C75 greatly increased the basal spike frequency of POMC neurons in the hypothalamic arcuate nucleus (Fig. 3). Although
C75 is known to inhibit FAS (7), its specificity for this enzyme is unclear. Another known FAS inhibitor, cerulenin, failed to
cause a significant increase in spike frequency, even at a dose 8-fold higher (9.1× higher in moles) than an effective dose of
C75. Results (mean ±SEM) were as follows (spike frequency, elapsed time after start of 60-min preincubation, number of
cells): control, 1.20 ± 0.16 Hz, 91.2 ± 1.6 min, 77 cells; 25 μM C75, 2.80 ± 0.38 Hz, 94.5 ± 2.2 min, 42 cells; 100 μM C75,
4.09 ± 0.45 Hz, 94.6 ± 2.3 min, 41 cells; 25 μMcerulenin, 1.08 ± 0.21 Hz, 93.6 ± 2.1 min, 45 cells; 100 μM cerulenin, 1.25 ±
0.30 Hz, 89.1 ± 2.3 min, 36 cells; 200 μM cerulenin, 0.86 ± 0.23 Hz, 94.9 ± 3.1 min, 22 cells.
Preincubation in C75 increased the basal firing rate of orexigenic arcuate nucleus NPY neurons
NPY/AGRP neuronal activation is normally associated with increased hunger. Therefore, if C75 reduces feeding through
normal physiological pathways, any C75 influence on arcuate NPY activity should be inhibitory. Unexpectedly, C75 greatly
increased the basal spike frequency of arcuate NPY neurons in a dose-dependent manner (Fig. 4). Here also, cerulenin did
not cause a significant increase in spike frequency. Results (mean ± SEM) were as follows (spike frequency, elapsed time
after start of 60-m preincubation, number of cells): control, 0.55 ± 0.10; 92.8 ± 1.5, 85; 25 μM C75, 2.35 ± 0.32, 93.8 ± 2.7,
28; 100 μM C75, 3.53 ± 0.37, 90.8 ± 2.5, 29; 100 μM cerulenin, 0.73 ± 0.17, 93.4 ± 2.3, 38; 200 μM cerulenin, 0.47 ± 0.18,
92.4 ± 2.9, 22.
Preincubation in C75 caused activation of cerebellar Purkinje neurons
Assuming that [malonyl-CoA] varies with feeding state in all neurons, because normal variations in feeding state do not
cause global neuronal modulation, neurons unrelated to feeding should be relatively insensitive to changes in [malonyl-CoA].
Therefore, if C75 inhibits feeding by boosting [malonyl-CoA], C75 should have no effect on neurons that are unrelated to
feeding. To test this idea, C75 was applied to cells with no hypothesized role in the regulation of hunger, cerebellar Purkinje
neurons.
Under our conditions, Purkinje neurons had relatively high spike frequencies at rest (48). As Purkinje neurons are
depolarized, they switch from a steady firing mode with constant spike amplitude to a bursting mode in which bursts of
action potentials are separated by silent pauses (49). Toward the end of each burst, spike frequency is so high that spike
amplitude shrinks because of inactivation.
Cerebellar slices were preincubated as before in control or C75 solutions. Purkinje cells were examined for 180 sec each to
determine whether firing was steady (Fig. 5A) or bursting (Fig. 5B) during that time. Mean spike frequency was determined
for nonbursting cells from 120 sec of recording. C75 greatly increased the proportion of Purkinje cells in bursting mode (Fig.
5C). For example, exposure to 100 μM C75 increased the proportion of Purkinje cells in bursting mode from 1 of 34 (2.94%)
to 11 of 14 (78.6%). Under control conditions, many Purkinje cells had relatively low spike frequencies, but this group was
no longer present after C75 incubation (Fig. 5D). C75 seemed to shift the frequency distribution upward, with the most
depolarized cells entering the bursting mode. Results (mean ± SEM) were as follows (proportion of cells exhibiting a bursting
firing pattern, spike frequency of nonbursting cells, time after start of 60 m preincubation): control, 1 of 34 cells (2.94%),
37.76 ± 3.11 Hz, 90.9 ± 2.4 min; 25 μM C75, 11 of 20 cells (55.0%), 46.34 ± 3.31 Hz, 91.3 ± 2.9 min; 50 μM C75, 7 of 10
cells (70.0%), 44.19 ± 2.33 Hz, 97.3 ± 4.5 min; 100 μM C75, 11 of 14 cells (78.6%), 62.93 ± 14.18 Hz, 87.9 ± 3.3 min.
Results
In vivo effects of C75
To confirm previous results (8, 10, 11) and the in vivo efficacy of our stock of C75, mice were injected with 15 mg/kg C75 or
a vehicle control. Four of five C75-treated mice ate much less and lost weight relative to vehicle-treated controls (Fig. 6).
Unexpectedly, these same four mice exhibited a diarrhea-like loosening of stools, which began within an hour of ip injection
and then worsened. Symptoms ranged from very soft, watery stools to feces the consistency of a slightly thickened liquid.
Stools were so soft that, after deposition in bedding, they were absorbed and lost within a few hours, perhaps explaining the
absence of previous reports of this effect. Detection depended on frequent postinjection observation and stool deposition on
food containers and on paper towels laid on the bedding for this purpose. The fifth C75-treated mouse ate robustly, lost no
weight, and displayed little, if any, softening of stool. Feces and weight of all vehicle-treated mice seemed to be unaffected.
C75 also disrupted normal nest-building behavior. By 18 h after injection, all mice unaffected by loosened stools had begun
to shred the paper towels left in their cages, whereas paper towels in the cages of the affected mice were completely intact,
consistent with visceral illness. Overall, at 24 h post injection, percent initial body weight was significantly less in C75-treated
mice (91.3 ± 2.4%, mean ± SEM, n = 5) than in vehicle-treated controls (100.1 ± 0.8%, P = 0.005, n = 6). In the 24 h after
injection, C75-treated mice ate only half as much (1.4 ± 0.48 g) as vehicle-treated mice (2.7 ± 0.33 g, mean ± SEM, P <
0.05).
To determine whether the loose/liquefied stools, weight loss, and decreased feeding produced by C75 were attributable to
inhibition of FAS, groups of four mice were injected with vehicle or cerulenin at 30, 60, and 120 mg/kg (Fig. 7). Even though
in moles, doses of cerulenin (MW 223.3) were 2.3×, 4.6×, and 9.1× the amount of C75 (MW 254.32) in a 15-mg/kg dose;
cerulenin did not induce loose stools at any dose. The effects of cerulenin on body weight and food consumption were also
small compared with C75. Only the highest dose of cerulenin (120 mg/kg) produced a significant decrease in body weight,
and the corresponding decrease in food consumption did not reach significance. Results (mean ± SEM) were as follows
(percent initial body weight, cumulative food consumption at 24 h post injection): control, 101.9 ± 1.2%, 2.8 ± 0.4 g; 30
mg/kg, 99.8 ± 0.8%, 2.8 ± 0.3 g; 60 mg/kg, 100.5 ± 0.8%, 2.5 ± 0.3 g; 120 mg/kg, 96.9 ± 1.3%, 1.7 ± 0.5 g.
It has been proposed that C75’s effects are mediated, in part, through activation of anorexigenic POMC/CART neurons of the
hypothalamic arcuate nucleus (11). The melanocortin-4 receptor (MC4-R) is thought to be the receptor most important in
mediating the effects of POMC on feeding. Therefore, we examined the role of MC4-R in mediating the actions of C75 using
MC4-RKO mice (13). Four MC4-RKO mice were conditioned with daily ip injections of vehicle for 5 d, during which they
steadily gained weight (Fig. 8). On the 6th day, all mice were injected with 15 mg/kg C75. In all mice, treatment with C75
was followed by abundant very soft or liquefied stool, decreased weight, and decreased food intake (Fig. 8). Soft stool was
first observed within 10, 17, 25, and 36 min of C75 injection. C75 caused a 24-h decrease in body weight of 12.4 ± 0.67%
(mean ± SEM), compared with a 2.0 ± 0.19% increase the day before (P = 0.000276). C75 caused a 66% drop in 24 h food
intake, from 2.17 ± 0.23 g the day before injection to 0.73 ± 0.09 g the day after (P = 0.0053). These results were consistent
with results described above in wild-type mice. Although body weight decreased by a small amount in the 3 h after each
vehicle injection (−1.9 ± 0.31% the day before C75), this decrease was much greater 3 h after C75 injection (−6.0 ±
0.27%, P = 0.0031; significance in all MC4-RKO experiments was evaluated using two-tailed, paired ttests).
In vitro
C75, a potent inducer of weight loss, was applied to anorexigenic arcuate POMC neurons, orexigenic arcuate NPY neurons,
and feeding-unrelated cerebellar Purkinje neurons, all of which were activated. Two lines of evidence suggest that this
activation was direct and not synaptic. First, to reduce synaptic input, antagonists of GABAA and ionotropic glutamate
receptors were included in all preincubations and recordings. Second, a direct, nonsynaptic effect is the simplest explanation
for the uniformity of response in two functionally antagonistic classes of hypothalamic neurons and in an unrelated type of
cerebellar neuron. This nonspecificity suggests that C75 has the potential to activate many other types of neurons, also.
However, in vivo, the effect of C75 on any given neuron would be the sum of direct effects and effects on presynaptic
neurons, making the net effect on any particular neuron hard to predict. A disproportionately large effect on inhibitory inputs
could potentially counterbalance C75-mediated excitation in certain neurons. Still, the final result would be network
dysregulation. When C75 is given centrally (8, 50), the neurological consequences of general neuronal activation, even if
mild, might explain the resulting inhibition of feeding. This hypothesis contradicts earlier conclusions about the mechanism by
which centrally administered C75 induces anorexia (51, 52). When given peripherally, because of limited central nervous
system (CNS) penetration (8), a dose of C75 sufficient to inhibit feeding might not be enough to cause obvious centrally
mediated behavioral deficits.
Early results with C75 met with great scientific interest because of the elegance of its proposed mechanism of action, in
which activity of feeding-related neurons is modulated by the increase in [malonyl-CoA] that results from FAS inhibition.
Although C75 activation of anorexigenic POMC neurons is consistent with this model, C75 activation of orexigenic
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NPY/AGRP neurons and cerebellar Purkinje neurons contradicts it. Even more convincing is the failure of even high
concentrations of cerulenin to mimic the effects of C75 on POMC and NPY neurons, which strongly suggests that C75-
induced neuronal activation is not a consequence of FAS inhibition. Finally, if increased [malonyl-CoA] caused the observed
activation, then normal postfeeding increases in [malonyl-CoA] would cause excitation of POMC, NPY, and Purkinje neurons
and, given C75’s apparent lack of target-specificity, perhaps even widespread neuronal excitation; but this does not occur.
Cerulenin is known to inhibit not only fatty acid synthesis (53) but also protein acylation (54,55, 56) and other processes
involving a similar reaction mechanism (53, 57) (although unlikely, it remains formally possible that these additional
properties of cerulenin block or compensate for the in vitro and in vivo effects that would otherwise be caused by its FAS
inhibitory activity). Because neither inhibition of FAS nor other cerulenin-like properties can account for our observations, C75
must have an additional activity. There are no data to preclude the existence of additional activities, and potential targets are
hard to predict. For example, it has recently been reported (58) that C75 activates CPT I, an enzyme required for fatty acid
metabolism, whereas indirect inhibition of CPT I had been predicted.
The extremely slow onset of C75-induced somatic excitation suggests gradual modulation of membrane conductances rather
than direct channel block. Possible mechanisms include reduced K+ channel activity or enhancement of depolarizing
conductances such as Ih (59) or subthreshold Na+ conductances (49, 60). Alternatively, if intracellular Ca2+ were decreased
(i.e. by decreasing Ca2+ channel activity, increasing Ca2+ extrusion, or other actions), the consequent reduction in
KCa activity could potentially trigger bursting or depolarization. Earlier work in Purkinje neurons suggests that such a
mechanism is possible (61, 62, 63). Finally, interference with ion transport could cause a gradual depolarization of
membrane potential and could also be involved in loosening of stools in vivo.
The concentrations of C75 (25–100 μM) used in these in vitro experiments were probably not unreasonably high. For
comparison, in previous studies, peak inhibition of feeding was obtained with 15 mg/kg ip (59.0 μmol/kg). 82% inhibition of
feeding was obtained with intracerebroventricular injection of 2 μl of 5.0 μg/μl (19.66 nmol/μl) C75 (8); and this translates into
39.3 μM, assuming even distribution into 1 ml of brain tissue, and a much higher initial concentration in CSF and
circumventricular areas such as the arcuate nucleus, which straddles the third ventricle. The ineffectiveness of cerulenin was
probably not attributable to insufficient drug. Cerulenin was used in vitro at concentrations similar to those used effectively in
other systems (53, 56, 64, 65, 66). Even though cerulenin has been shown to be more potent than C75 in inhibiting growth
of fibroblasts and a breast cancer cell line (7), cerulenin was still ineffective at 8× (200 μM) the effective concentration of C75
(25 μM).
Loose-patch extracellular recording from POMC, NPY, and Purkinje neurons seems to be a useful way to test potential
anorexigenic drugs for selectivity. Because small changes in membrane potential can have large effects on neuronal output
(action potentials), extracellular recording is a sensitive and reliable method for testing compounds with potentially weak
somatic effects.
In vivo
When given ip, C75 rapidly caused stool to become extremely loose or liquid, and this was accompanied by weight loss,
decreased food intake, and inhibition of normal paper-shredding behavior. All of these effects are consistent with visceral
illness. It has been reported that peripheral, but not central, administration of C75 induces visceral illness in rats (Ref. 50 ,
but see Ref. 67), although loose stools have not been reported. In contrast, cerulenin did not induce loose stools, even at a
molar dose over 9-fold that of C75, suggesting that FAS inhibition was not responsible for this effect. Cerulenin also
decreased food intake and body weight much less effectively than C75.
It is possible that loosening of stools and weight loss/anorexia are both manifestations of a C75-induced visceral illness (50).
If so, then the inability of cerulenin to loosen stools would suggest that it does not induce a C75-type of visceral illness, and
this would explain the relative weakness of cerulenin’s anorexigenic activity. But if loose stools and anorexia are both parts of
a visceral illness that cannot be reproduced by cerulenin, then it follows that these effects do not result from FAS inhibition.
This conclusion contradicts current hypotheses about the mechanism of C75-induced weight loss (8, 51, 52). On the other
hand, the inability of cerulenin to reproduce the actions of C75 could result from low penetrance into the CNS, rapid
inactivation, or rapid clearance relative to C75. It is also possible that the extreme loosening of stools and the weight
loss/anorexia induced by ip C75 are unrelated.
Our results with cerulenin are consistent with an earlier report in rat in which, even after extended administration, the effect
of cerulenin was very modest (68), although a more substantial effect was seen in a different report in mice (8). Cerulenin
interferes with numerous physiological processes (64, 65, 69, 70), and where mechanism has been determined, it has often
been found to result from inhibition of protein acylation (55, 56, 66,71, 72) rather than fatty acid synthesis (73). Given this
nonspecificity, and the extremely high doses typically required, the mechanism by which cerulenin induces weight loss is
unclear.
In all treated MC4-RKO mice, C75 induced abundant very soft or liquefied stools, weight loss, and decreased food intake,
and results were similar to those in wild-type mice. Therefore, C75 does not require the receptor most responsible for the
influence of POMC on feeding. This is consistent with an earlier report showing that in ob/ob mice, the effect of C75 was
undiminished, despite a lack of effect on hypothalamic POMC expression (11).
Given its in vitro nonspecificity, C75 might cause visceral illness by activating neurons of the area postrema (AP) or enteric
nervous system. Diarrhea usually results from decreased absorption of electrolytes and water and/or increased active
secretion of anions into the intestinal lumen (74). To this end, C75 could directly affect ion transport in the intestinal
epithelium. Alternatively, C75 could activate intestinal smooth muscle, another excitable cell type, in such a way as to cause
hypermotility and reduce time available for water uptake (74). However, our data do not address these possibilities. It is also
possible that the AP, a critical CNS sensor of circulating toxins that is involved in nausea and vomiting (75), interprets C75
as a toxin. Part of the adjacent nucleus tractus solitarius (NTS) is also involved in regulating feeding (76, 77). Both are
especially attractive potential CNS targets of C75, because the AP and part of the NTS lie outside the blood brain barrier
(75, 78). It has been reported recently that ip administration of C75 is followed rapidly by induction of c-Fos expression in the
AP and NTS (52). Although only a small proportion of ip-injected C75 reaches the rest of the brain (8), a direct C75 effect
there cannot be excluded, especially at other sites where the blood-brain barrier is weak or absent.
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Abbreviations: AGRP, Agouti-related protein; AP, area postrema; CART, cocaine and amphetamine regulated transcript; CoA,
coenzyme A; CNS, central nervous system; CPT I, carnitine palmitoyltransferase I; DMSO, dimethylsulfoxide; EGFP,
enhanced green fluorescent protein; FAS, fatty acid synthase; GABA, γ-aminobutyric acid; NPY, neuropeptide Y; NTS,
nucleus tractus solitarius; POMC, proopiomelanocortin; RKO, receptor knockout; SAP, sapphire fluorescent protein.
FIG. 1. Fatty acid synthesis. Inhibition of FAS
causes malonyl-CoA concentration to
increase, probably by both decreasing its
utilization and increasing its synthesis.
Normally, palmitoyl-CoA inhibits both citrate
translocation and allosteric activation of
acetyl-CoA carboxylase by citrate; but by
blocking palmitate production, C75 could
release this inhibition, resulting in increased
synthesis of malonyl-CoA.
FIG. 2. After a 10-min delay, C75 induced a
steady increase in the spike frequency of
arcuate POMC neurons that continued even
after perfusion with control saline was
restored. This increase seemed to be
preceded by a small, transient decrease in
firing rate, especially at 100 μM C75. Data
are plotted as mean ± SEM in 60-sec bins. **,
Significantly different from control (P <
0.001); ANOVA was followed by Student-
Newman-Keuls multiple-comparison post
test.
FIG. 3. Preincubation in C75 increased the
basal firing rate of arcuate POMC neurons. A
and B, Representative traces from recordings
of POMC neurons after preincubation in
control saline or 100 μM C75. C,
Preincubation in C75, but not cerulenin,
greatly increased the basal spike frequency
of POMC neurons. Preincubations and
recordings in all experiments were conducted
in the presence of 1 mM kynurenic acid and
100 μM picrotoxin to block ionotropic
glutamate receptors and GABAA receptors.
Data are plotted as mean ±SEM. *,
Significantly different from control (P < 0.01);
**, significantly different from control (P<
0.001); Kruskal-Wallis test was followed by
Dunn’s multiple-comparison post test; 25
μMand 100 μM C75 results were not
significantly different from each other.
FIG. 4. Preincubation in C75, but not
cerulenin, greatly increased the basal spike
frequency of arcuate nucleus NPY neurons.
**, Significantly different from control (P <
0.001); Kruskal-Wallis test was followed by
Dunn’s multiple-comparison post test; 25
μMand 100 μM C75 results were not
significantly different from each other. Data
are plotted as mean ± SEM.
FIG. 5. Preincubation in C75 changed the
firing mode and frequency distribution of
cerebellar Purkinje cells. A, Stable firing
mode in a control Purkinje cell. B, Bursting
mode in a Purkinje cell preincubated in 100
μM C75. C, C75 induced a dose-dependent
increase in the proportion of cells in bursting
mode that was statistically significant by
χ2 test (P < 0.0001). D, Spike frequencies of
all nonbursting Purkinje cells. Cells with low
spike frequencies are rare after exposure to
C75. C75 incubation seemed to shift cells
either to higher spike frequencies or into
bursting mode.
FIG. 6. Injection ip of 15 mg/kg C75 induced
weight loss, a large decrease in food
consumption, and very loose/liquefied stools.
Vehicle, n = 6. C75, n = 5. A, Weight of
individual mice, 24 h after injection with C75
or vehicle, displayed as percent initial weight.
C75-induced weight loss was associated with
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